NASDAQ:QDEL - Quidel Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $180.25
Forecasted Upside: 60.89 %
Number of Analysts: 4
Breakdown:
1 Sell Ratings
0 Hold Ratings
3 Buy Ratings
0 Strong Buy Ratings

^$112.03 As of 06/16/2021 01:00 AM ET

▲ +1.03 (0.93%)

1 month | 3 months | 12 months

Get New Quidel Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for QDEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QDEL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$180.25

▲ +60.89% Upside Potential

This price target is based on 4 analysts offering 12 month price targets for Quidel in the last 3 months. The average price target is $180.25, with a high forecast of $341.00 and a low forecast of $80.00. The average price target represents a 60.89% upside from the last price of $112.03.

Buy

The current consensus among 4 contributing investment analysts is to buy stock in Quidel. This rating has held steady since March 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

12/24/2019

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/23/2020

0 strong buy ratings
3 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

6/21/2020

0 strong buy ratings
4 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

9/19/2020

0 strong buy ratings
3 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

12/18/2020

0 strong buy ratings
3 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

3/18/2021

0 strong buy ratings
3 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

5/17/2021

0 strong buy ratings
3 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

6/16/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
6/4/2021	JPMorgan Chase & Co.	Lower Price Target	Underweight	$90.00 ➝ $80.00	High	i
5/7/2021	Raymond James	Lower Price Target	Outperform	$180.00 ➝ $160.00	High	i
5/7/2021	JPMorgan Chase & Co.	Lower Price Target	Underweight	$95.00 ➝ $90.00	High	i
4/23/2021	JPMorgan Chase & Co.	Lower Price Target		$120.00 ➝ $95.00	High	i
4/23/2021	Piper Sandler	Lower Price Target		$265.00 ➝ $140.00	High	i
3/17/2021	Raymond James	Lower Price Target	Outperform	$245.00 ➝ $180.00	N/A	i
3/11/2021	Craig Hallum	Lower Price Target	Buy	$371.00 ➝ $341.00	Low	i
3/11/2021	Raymond James	Lower Price Target	Outperform	$245.00 ➝ $180.00	Low	i
2/25/2021	Raymond James	Lower Price Target	Outperform	$250.00 ➝ $245.00	Medium	i
2/19/2021	JPMorgan Chase & Co.	Lower Price Target	Underweight	$175.00 ➝ $170.00	High	i
1/22/2021	Raymond James	Upgrade	Market Perform ➝ Outperform	$250.00	High	i
10/30/2020	JPMorgan Chase & Co.	Boost Price Target	Underweight	$185.00 ➝ $190.00	Medium	i
7/31/2020	Craig Hallum	Boost Price Target	Positive ➝ Buy	$306.00 ➝ $363.00	Medium	i
7/31/2020	Piper Sandler	Boost Price Target	Overweight	$250.00 ➝ $360.00	High	i
7/8/2020	Piper Sandler	Boost Price Target	Overweight	$168.00 ➝ $250.00	Medium	i
7/7/2020	Craig Hallum	Boost Price Target	Buy	$170.00 ➝ $306.00	Medium	i
5/12/2020	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$120.00 ➝ $158.00	High	i
5/7/2020	Craig Hallum	Boost Price Target	Market Perform ➝ Buy	$125.00 ➝ $170.00	Medium	i
3/26/2020	Barclays	Reiterated Rating	Overweight ➝ Equal Weight	$90.00	High	i
3/19/2020	Raymond James	Downgrade	Strong-Buy ➝ Market Perform		High	i
2/13/2020	Raymond James	Boost Price Target	Strong-Buy	$70.00 ➝ $92.00	Medium	i
11/17/2019	Canaccord Genuity	Reiterated Rating	Buy	$70.00 ➝ $75.00	Low	i
8/29/2019	Craig Hallum	Upgrade	Hold ➝ Buy	$63.00 ➝ $75.00	High	i
7/1/2019	Canaccord Genuity	Reiterated Rating	Buy	$70.00	Low	i
4/15/2019	Raymond James	Boost Price Target	Strong-Buy ➝ Strong-Buy	$72.00 ➝ $74.00	Medium	i Rating by John Hsu at Raymond James
3/18/2019	Barclays	Boost Price Target	Overweight ➝ Overweight	$74.00 ➝ $77.00	High	i
2/15/2019	Barclays	Reiterated Rating	Buy	$74.00	Low	i
2/14/2019	Craig Hallum	Boost Price Target	Hold	$51.00 ➝ $63.00	High	i Rating by Alexander Nowak at Craig Hallum
12/11/2018	Raymond James	Lower Price Target	Strong-Buy ➝ Strong-Buy	$80.00 ➝ $70.00	Medium	i Rating by John Hsu at Raymond James
12/11/2018	Canaccord Genuity	Downgrade	Buy		High	i
12/10/2018	Craig Hallum	Downgrade	Buy ➝ Hold	$80.00 ➝ $51.00	High	i
12/10/2018	Barclays	Lower Price Target	Overweight ➝ Overweight	$85.00 ➝ $77.00	High	i
10/23/2018	Raymond James	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$80.00	Medium	i
9/10/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $80.00	Low	i
8/14/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$75.00 ➝ $78.00	Low	i
8/8/2018	Craig Hallum	Boost Price Target	Buy	$64.00 ➝ $80.00	High	i Rating by Alexander Nowak at Craig Hallum
8/8/2018	Piper Jaffray Companies	Reiterated Rating	In-Line ➝ Overweight	$74.00	High	i
8/6/2018	Barclays	Boost Price Target	Overweight ➝ Overweight	$65.00 ➝ $78.00	Medium	i
5/10/2018	Barclays	Reiterated Rating	Buy	$65.00	High	i
4/13/2018	William Blair	Reiterated Rating	Buy		Low	i
4/5/2018	Canaccord Genuity	Boost Price Target	Buy	$55.00 ➝ $64.00	Low	i
4/4/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$63.00	Low	i
4/2/2018	Barclays	Boost Price Target	Overweight ➝ Overweight	$60.00 ➝ $63.00	Low	i
3/26/2018	Craig Hallum	Initiated Coverage	Buy	$62.00	Low	i
3/8/2018	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$55.00 ➝ $47.00	Medium	i
3/8/2018	UBS Group	Upgrade	Outperform ➝ Strong-Buy		High	i
1/24/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$60.00	Low	i
1/22/2018	Barclays	Boost Price Target	Overweight ➝ Overweight	$50.00 ➝ $60.00	High	i
1/4/2018	CL King	Upgrade	Neutral ➝ Buy	$52.00	High	i
12/21/2017	Canaccord Genuity	Reiterated Rating	Buy	$48.00 ➝ $52.00	Medium	i
12/14/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$50.00	Low	i
11/3/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$50.00	N/A	i
11/2/2017	Barclays	Boost Price Target	Overweight	$45.00 ➝ $49.00	N/A	i
10/25/2017	Canaccord Genuity	Reiterated Rating	Buy	$48.00	N/A	i
9/19/2017	Canaccord Genuity	Reiterated Rating	Buy	$42.00 ➝ $48.00	High	i
9/19/2017	Barclays	Reiterated Rating	Buy	$39.00 ➝ $45.00	High	i
9/19/2017	Raymond James	Reiterated Rating	Buy	$41.00 ➝ $47.00	High	i
9/19/2017	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight	$35.00 ➝ $50.00	High	i
7/27/2017	Raymond James	Boost Price Target	Outperform	$36.00 ➝ $41.00	High	i
7/27/2017	Barclays	Boost Price Target	Overweight	$36.00 ➝ $39.00	High	i
7/18/2017	William Blair	Upgrade	Market Perform ➝ Outperform		High	i
7/18/2017	Canaccord Genuity	Upgrade	Hold ➝ Buy		High	i Rating by Mark Massaro at Canaccord Genuity
5/19/2017	Canaccord Genuity	Reiterated Rating	Hold	$24.50 ➝ $25.00	Low	i Rating by Mark Massaro at Canaccord Genuity
4/26/2017	Barclays	Boost Price Target	Overweight	$26.00 ➝ $27.00	Low	i
4/25/2017	Canaccord Genuity	Reiterated Rating	Hold	$24.00 ➝ $24.50	High	i Rating by Mark Massaro at Canaccord Genuity
2/17/2017	CL King	Initiated Coverage	Neutral		N/A	i
1/23/2017	Canaccord Genuity	Reiterated Rating	Hold	$22.00	N/A	i Rating by Mark Massaro at Canaccord Genuity
12/16/2016	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$22.00	N/A	i
10/27/2016	Canaccord Genuity	Set Price Target	Hold	$22.00	N/A	i Rating by Mark Massaro at Canaccord Genuity
7/29/2016	Canaccord Genuity	Reiterated Rating	Hold	$22.00	N/A	i Rating by Mark Massaro at Canaccord Genuity

(Data available from 6/16/2016 forward)

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.

Today's Range

Now: $112.03

$109.89

$113.07

50 Day Range

MA: $116.55

$104.07

$129.60

52 Week Range

Now: $112.03

$103.31

$306.72

Volume

354,638 shs

Average Volume

923,788 shs

Market Capitalization

$4.77 billion

P/E Ratio

5.15

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Quidel?

The following sell-side analysts have issued reports on Quidel in the last twelve months: Craig Hallum, JPMorgan Chase & Co., Piper Sandler, Raymond James, and Zacks Investment Research.
View the latest analyst ratings for QDEL.

What is the current price target for Quidel?

4 Wall Street analysts have set twelve-month price targets for Quidel in the last year. Their average twelve-month price target is $180.25, suggesting a possible upside of 61.0%. Craig Hallum has the highest price target set, predicting QDEL will reach $341.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $80.00 for Quidel in the next year.
View the latest price targets for QDEL.

What is the current consensus analyst rating for Quidel?

Quidel currently has 1 sell rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe QDEL will outperform the market and that investors should add to their positions of Quidel.
View the latest ratings for QDEL.

What other companies compete with Quidel?

Other companies that are similar to Quidel include Align Technology, West Pharmaceutical Services, The Cooper Companies, DENTSPLY SIRONA, STAAR Surgical, Neogen, ICU Medical, Merit Medical Systems, Haemonetics, Atrion, Cerus, Meridian Bioscience, Antares Pharma, OraSure Technologies and Anika Therapeutics.

How do I contact Quidel's investor relations team?

Quidel's physical mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The company's listed phone number is 858-552-1100 and its investor relations email address is [email protected] The official website for Quidel is www.quidel.com.